Your session is about to expire
← Back to Search
AZD0901 arm 1 for Gastroesophageal Junction Cancer
Study Summary
This trial aims to compare the effectiveness and safety of AZD0901 with other treatment options for patients with advanced stomach or gastroesophageal junction cancer that has spread, and that expresses a specific protein
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
In how many distinct settings is this research study being conducted?
"The research project is active at a total of 101 sites, with facilities in cities such as Kansas City, Portland, and Changsha among others. It is advisable to choose the nearest clinic for convenience and to reduce travel commitments upon enrollment."
Which specific criteria determine the inclusion of individuals into this research study?
"Individuals aged between 18 and 130 diagnosed with gastric cancer are sought for this clinical investigation, aiming to recruit approximately 589 participants."
Does this medical study enroll individuals who are aged 55 years or older?
"This investigation seeks individuals over 18 years old but under the age of 130 to participate."
Is the enrollment process open for this medical study at present?
"Yes, the information on clinicaltrials.gov indicates that this trial is currently seeking volunteers. The trial was initially listed on March 4, 2024, and its most recent update was on March 28, 2024. A total of 589 participants are sought across a network of 101 sites."
Has the first arm of the AZD0901 trial received approval from the Food and Drug Administration?
"According to our team at Power, the safety rating for arm 1 of AZD0901 is a 3 on the scale due to its Phase 3 status. This suggests that there exists some evidence supporting its effectiveness and multiple datasets affirming its safety profile."
What is the total number of individuals currently under research in this clinical trial?
"Indeed, the details available on clinicaltrials.gov indicate that this investigation is actively seeking eligible participants. Initially shared with the public on March 4th, 2024, and most recently revised on March 28th, 2024, this study aims to enroll a total of 589 patients distributed across 101 medical sites."
Share this study with friends
Copy Link
Messenger